Cancer research
Trials across solid tumours, blood cancers, immunotherapy and supportive care.
4,193 indexed studies · 1,755 currently recruiting
Top conditions in this hub
Recent studies
- Ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
A Phase 1, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 as Monotherapy in Patients with Selected Advanced Solid Tumors
This study is testing a new medicine, ADCT-901, for people with advanced cancers that have spread. It's the first time this medicine is being given to humans, to see how safe it is, what side effects it has, and if it helps shrink tumours.
Spain - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 Study of Intratumoral Injection of LTX-315 in Combination with Pembrolizumab in Patients with Percutaneously Accessible Lesions with Advanced Melanoma Refractory to PD-1/PD-L1 Inhibitor Therapy
This study looks at a new treatment for advanced melanoma that has not responded to previous immunotherapy. It combines an injected drug (LTX-315) with an existing cancer drug (Pembrolizumab) to see if it can shrink tumours and extend life. Researchers will closely monitor participants' health.
France · Norway · Spain - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 Study of Neoadjuvant Cemiplimab for Stage II to IV (M0) Cutaneous Squamous Cell Carcinoma (CSCC)
This study is testing a new medicine, cemiplimab (also known as Libtayo), for a type of skin cancer called cutaneous squamous cell carcinoma. Doctors want to see if giving this medicine before surgery can completely clear the cancer cells at the original site.
Germany - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Various Combinations of BGB-A425 and LBL-007 with Tislelizumab in Patients with Advanced Solid Tumors
This study looks at new drug combinations (BGB-A425, LBL-007, and Tislelizumab) for advanced head and neck, kidney, and lung cancers. It aims to find safe doses and see if they shrink tumours. It's an early-stage study.
France · Spain · Poland - Ongoing, recruitingTherapeutic exploratory (Phase II)
A MULTICOHORT, OPEN LABEL, PHASE 2 STUDY OF BOTENSILIMAB (AGEN1181) FOR TREATMENT OF ADVANCED MELANOMA REFRACTORY TO PRIOR CHECKPOINT INHIBITOR THERAPY
This study is testing new medicines, botensilimab and balstilimab, for adults with advanced melanoma. These are cancers that have not responded to previous treatments. We want to see if the new medicines can shrink the cancer.
Belgium · Germany · Italy - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase I/II study to evaluate the feasibility, safety and preliminary efficacy of point-of-care manufactured anti-CD19 CAR T in subjects with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
This study is looking at a new treatment called BCN-CP01 for people with certain types of blood cancer (relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma) that have come back or not responded to previous treatments. It aims to see if the treatment is safe and if it helps patients get better.
Spain · Belgium · Netherlands - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
Phase 1b study investigating the association of NP137 with mFOLFIRINOX in locally advanced pancreatic ductal adenocarcinoma LAP NET 1
This study is looking at a new treatment called NP137 when given alongside a common chemotherapy for pancreatic cancer. It's for adults with a type of pancreatic cancer that hasn't spread far but can't be removed by surgery. The aim is to see if these treatments work well together.
France - Ongoing, recruitingTherapeutic exploratory (Phase II)
Ezurpimtrostat autophagy inhibitor in association with Atezolizumab-Bevacizumab in first line treatment of unresectable hepatocellular carcinoma, a phase 2b randomized trial. ABE-LIVER
This study is testing a new drug, Ezurpimtrostat, alongside standard treatments (Atezolizumab and Bevacizumab) for advanced liver cancer that can't be removed by surgery. It aims to see how well this new combination stops the cancer from growing.
France - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase 1 Study of the SHP2 Inhibitor BBP-398 (formerly known as IACS-15509) in combination with the KRAS-G12C Inhibitor Sotorasib in Patients with Advanced Solid Tumors and a KRAS-G12C Mutation
This study is testing a new combination of two medicines for people with advanced cancers that have a specific genetic change (called KRAS-G12C). One medicine is new (BBP-398), and it's being given with an existing one (sotorasib) to see if they work better together.
Netherlands · Spain · France - Ongoing, recruitingTherapeutic use (Phase IV)
The Intertransverse Process Block - Single or Multiple Injection? A randomised, procedure related, blinded crossover trial in healthy volunteers
This study is looking at a pain-relief method called an 'Intertransverse Process Block' in healthy men. Researchers are comparing one injection to multiple injections to see which works better for numbing areas of the chest. It's about finding the best way to help with pain, especially after breast cancer surgery.
Denmark - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)
This study looks at a new drug, pembrolizumab (Keytruda), combined with another medicine, enzalutamide. It's for men with advanced prostate cancer that has spread and isn't responding to hormone treatment. We want to see if this combination helps men live longer and slows down the cancer's growth.
Austria · Italy · Netherlands - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
First-in-Human, Open-label, Dose-Escalation Trial with Expansion Cohorts to Evaluate the Safety of GEN1053 as Monotherapy and in Combination With an Immunomodulator in Subjects with Malignant Solid Tumors
This study is testing a new medicine called HexaBody-CD27 for people with solid tumours that have spread. It's looking at how safe the medicine is, how much to give, and if it can help shrink tumours. It's an early-stage study to understand this new treatment better.
Spain - Ongoing, recruitingTherapeutic exploratory (Phase II)
Phase 2, Open-Label Study in Subjects with Previously Untreated MET Amplified Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
This study is testing a new medicine, Telisotuzumab Vedotin, for people with a specific type of lung cancer that hasn't been treated before. Researchers want to see how well it shrinks tumours and helps patients feel better. It's an important step in finding new treatments.
Romania · Germany · Italy - Ongoing, recruitingTherapeutic exploratory (Phase II)
Randomized Phase 2 Study of DKN-01 Plus FOLFIRI/FOLFOX and Bevacizumab Versus FOLFIRI/FOLFOX and Bevacizumab as Second-line Treatment of Advanced Colorectal Cancer (DeFianCe)
This study looks at a new drug, DKN-01, combined with standard treatments for advanced bowel cancer. It compares this new combination to the standard treatments alone, to see if it helps people live longer without their cancer growing.
Germany - RecruitingNA
IMPLEMENT - Model Project for Quality-assured Exercise Therapy for Cancer Patients
This project aims to make sure cancer patients in Germany can easily access high-quality exercise programmes. It will find out what helps and what makes it difficult for people to join these programmes, and then create better ways for everyone to get involved.
Germany - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A 3-Part Phase 1 Study to Investigate the Absolute Oral Bioavailability and Absorption, Metabolism, and Excretion of 14C-Unesbulin in Patients With Advanced Solid Tumor
This early-stage study is testing a new medicine called Unesbulin, marked with a special tracer, in people with advanced solid tumours. Researchers want to understand how the body takes in, uses, and gets rid of this medicine when taken by mouth.
Hungary - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase 1/2 Open-Label Multicenter Trial to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects with BRAF-V600 Mutant Solid Tumors.
This study is testing a new medicine, CFT1946, for people with certain types of cancer that have a specific BRAF gene change. It checks if the medicine is safe, how well it's tolerated, and if it can shrink tumors or stop them growing, both alone and with other treatments.
France · Spain · Italy - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
Phase 1 study of NG-641 plus nivolumab (or standard of care PD-1) in metastatic or advanced epithelial tumours (NEBULA)
This study is looking into a new treatment called NG-641, used with an existing cancer medicine (nivolumab or similar), for people with advanced or spreading cancer. It's a very early-stage trial, focusing on safety and how the new treatment works in the body.
Belgium · Spain - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase 1/2 Study of BMS-986408 Alone and in Combination with Nivolumab or with Nivolumab and Ipilimumab in Participants with Advanced Solid Tumors
This study is testing a new drug, BMS-986408, alone and with existing cancer drugs, nivolumab and ipilimumab, for advanced solid tumours. It aims to see how safe the new drug is and what side effects it might cause, as well as how well it works.
France · Spain - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase 1/2 Study of the Safety, Pharmacokinetics and Anti-Tumor Activity of the Oral KIT Inhibitor THE-630 in Patients with Advanced Gastrointestinal Stromal Tumors (GIST)
This study is testing a new medicine, THE-630, for people with a type of cancer called GIST. It's looking at how safe the medicine is, how it moves through the body, and if it helps shrink tumours. It's in early stages, checking different doses.
Spain · France - Ongoing, recruitingTherapeutic exploratory (Phase II)
"DEMETER": Milademetan and fulvestrant in GATA3-mutant, ER-positive, HER2-negative advanced or metastatic breast cancer patients: a multicenter phase II trial
This study is testing a new drug, milademetan, alongside an existing treatment, fulvestrant, for a specific type of advanced breast cancer. Researchers want to see if this combination helps shrink tumours or stop their growth in patients with certain genetic markers.
France - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
Phase 1 study of NG-350A plus pembrolizumab in metastatic or advanced epithelial tumours (FORTIFY)
This study, called FORTIFY, is testing a new treatment called NG-350A along with an existing cancer drug, pembrolizumab. It's for adults with advanced or spreading cancers that start in the lining of organs, like skin or glands. This is an early-stage study to see if the treatment is safe.
Belgium · Spain - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
Z0011001-A PHASE 1/2, OPEN-LABEL, MULTI-CENTER STUDY OF ZN-c3 ADMINISTERED IN COMBINATION WITH ENCORAFENIB AND CETUXIMAB IN ADULTS WITH METASTATIC COLORECTAL CANCER
This study is testing a new combination of medicines for people with bowel cancer that has spread. We want to see if a new drug called Azenosertib, given with two existing drugs (Encafenib and Cetuximab), is safe and helps shrink the cancer. This is an early-stage study.
Poland · Spain · Germany - Ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
A Phase 1, Open-label, Multicenter Study of the Safety, Pharmacokinetics, and Pharmacodynamics of MK-4464 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced/Metastatic Solid Tumors
This early-stage study is testing a new medicine, MK-4464, alone and with another drug (pembrolizumab). It's for adults with advanced cancers to see if it's safe, how it moves through the body, and what effects it has. This is one of the first times it's being used in people.
Netherlands - RecruitingNA
Lymph Node Mapping Via Flourescent Dye in Colon Cancer
This study looks at how cancerous colon cells spread to nearby lymph nodes. We use a special dye and camera during surgery to see if these nodes are always found in the usual places, or sometimes outside, which could help guide treatment.
Germany - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
Phase 1b study to evaluate MK 0482 for Relapsed/Refractory AML/CMML
This early-stage study is looking at a new medicine called MK 0482 for adults with certain types of blood cancer (AML or CMML) that have come back after treatment or haven't responded well. It aims to see if the medicine is safe and how it works.
Spain - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase 1 Study of BMS-986360/CC-90001 Alone and in Combination with Chemotherapy or Nivolumab in Advanced Solid Tumors
This study is testing a new medicine, BMS-986360/CC-90001, for people with advanced solid cancers. It will see how safe the medicine is when given alone or with other cancer treatments like chemotherapy or nivolumab. It's an early-stage study, meaning it's the first time it will be widely used in people.
Italy · Spain · France - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501A, an Anti-CD19 Allogeneic CAR T Cell Therapy, and ALLO-647, an Anti-CD52 Monoclonal Antibody, in Subjects with Relapsed/Refractory Large B Cell Lymphoma (LBCL).
This study is testing a new cell therapy called ALLO-501A, along with another drug called ALLO-647, for adults with a type of blood cancer called Large B-Cell Lymphoma, where previous treatments haven't worked. It aims to see how safe and effective these new treatments are.
Italy · Spain - Ongoing, recruitingTherapeutic exploratory (Phase II)
SAFIR 03_A ctDNA screening program in patients with HR+, HER2- metastatic breast cancer for detection of high-risk relapse patients on any CDK4/6 inhibitor and a randomised phase II study comparing alpelisib combined with fulvestrant to ribociclib combined with fulvestrant, in patients with persistent targetable PIK3CA mutations.
This study looks at new ways to treat advanced breast cancer that has spread. It's for women with a specific type of hormone-positive breast cancer. Researchers are comparing two different drug combinations to see which works best at stopping the cancer from growing.
France - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 1/Phase 2 Study to Evaluate the Safety and Tolerability of MK-1088 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors
This study is testing a new cancer medicine, MK-1088, sometimes with an existing medicine called Pembrolizumab (Keytruda). We want to find out if it's safe for people with advanced solid tumours and how well it's tolerated. It's an early-stage study focusing on safety.
Denmark - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Study to Estimate the Effect of Multiple Doses of Carbamazepine on the PK of Single Dose Vepdegestrant in Healthy Adult Participants
This study is looking at how a common seizure medication, carbamazepine, affects a new breast cancer drug called vepdegestrant in healthy adults. It's an early-stage study to understand how these medicines interact in the body.
Belgium - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
Study evaluating PSMA targeted radionuclide therapy in adult patients with metastatic clear cell renal cancer
This study is looking at a new type of radiation treatment for clear cell kidney cancer that has spread. It focuses on patients whose cancer has grown despite previous treatments, including anti-VEGFR and immunotherapy. The aim is to see if this new treatment can help.
France - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2a, double-blind, placebo-controlled, multi-center, randomized study evaluating LSTA1 when added to standard of care (SoC) versus standard of care alone in subjects with advanced solid tumors (BOLSTER)
This study is looking at a new treatment called LSTA1 for people with advanced head and neck cancer or a type of bile duct cancer (cholangiocarcinoma). It aims to see if adding LSTA1 to standard treatments is safe and helps people live longer and feel better.
Spain - Ongoing, recruitingTherapeutic exploratory (Phase II)
Phase II trial of trastuzumab deruxtecan in first-line treatment HER2-positive locally advanced or metastatic breast cancer (MBC) patients considered resistant to trastuzumab + pertuzumab + taxane due to early relapse. “TRANSCENDER Study”
The TRANSCENDER study is a clinical trial looking at a new treatment called trastuzumab deruxtecan (DS-8201a) for advanced breast cancer. It's for patients whose cancer has come back quickly after standard treatments. We want to see how well this new treatment shrinks the cancer.
Spain - Ongoing, recruitingTherapeutic exploratory (Phase II)
"neoBREASTIM": A Phase 2 Study of Atezolizumab plus RP1 oncolytic immunotherapy in the NeoAdjuvant setting of Triple-Negative Breast Cancer (TNBC)
This study is testing new ways to treat a type of breast cancer called Triple Negative Breast Cancer (TNBC) before surgery. It combines two medicines, Tecentriq and Vusolimogene oderparepvec, to see if they are safe and help reduce the amount of cancer. It's an early-stage study.
France - Ongoing, recruitingTherapeutic exploratory (Phase II)
A PHASE 2 STUDY EVALUATING INCB099280 IN PARTICIPANTS WITH SELECT SOLID TUMORS WHO ARE IMMUNE CHECKPOINT INHIBITOR–NAÏVE
This study is testing a new medicine called INCB099280 for people with certain advanced solid cancers that haven't been treated with immunotherapy before. Researchers want to see if the medicine shrinks tumors and how safe it is.
Romania · Hungary · Greece - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase 1 Study to Assess Mass Balance, Pharmacokinetics, and Metabolism of [14C]Subasumstat in Patients With Advanced or Metastatic Solid Tumors
This early-stage study is for adults with advanced or spreading solid cancers. It aims to understand how a new medicine, called Subasumstat, moves through and is used by the body. Researchers will also look at how the body breaks down this medicine and what happens to it afterwards.
Hungary - Ongoing, recruitingTherapeutic exploratory (Phase II)
CT7001_002 (SUMIT-BC) - An open-label Interventional, Multicenter, Randomized, Phase 2 Study of Fulvestrant with or without Samuraciclib in Participants with Metastatic or Locally Advanced Hormone Receptor Positive and Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
This study is looking at a new drug (Samuraciclib) combined with a standard breast cancer treatment (Fulvestrant) for advanced or spread hormone-sensitive breast cancer. Doctors want to see if this new combination works better at shrinking tumours or stopping them from growing for a longer time.
Spain · Hungary - Active not recruitingPHASE2
Belimumab in Patients with Chronic Lymphocytic Leukemia
This study looks at adding a new drug, belimumab, to standard treatment (rituximab/venetoclax) for chronic lymphocytic leukemia (CLL) that has come back or isn't responding. The aim is to make the treatment work better and potentially reduce its overall length.
Germany - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A study to learn how BAY2927088 is taken up and handled by the body in healthy male participants
This study is looking at how a new medicine, BAY2927088, works in the body of healthy men. It aims to understand how much medicine is absorbed, how it moves through the body, and how it's removed. This information will help researchers understand its potential for treating certain lung cancers.
Netherlands